Literature DB >> 25473178

Budd-Chiari syndrome: a single-center experience.

Tanya M Pavri1, Alan Herbst1, Rajender Reddy1, Kimberly A Forde1.   

Abstract

AIM: To investigate challenges, risk factors, prognostic indicators, and treatment outcomes associated with Budd-Chiari syndrome (BCS) at a tertiary care center.
METHODS: A retrospective cohort study was conducted at the University of Pennsylvania in patients with a diagnosis of BCS or hepatic vein thrombosis. All patients receiving care at the University of Pennsylvania, and who had at least 2 clinical encounters in the University of Pennsylvania Health system from January 1, 2008 to September 10, 2013 were eligible for study inclusion. Data were extracted from the electronic medical record of each patient, and recorded in a secure Research Electronic Data Capture database. Logistic regression analyses were applied to identify predictors of outcome of liver transplant (LT) or death.
RESULTS: Between January 1, 2008 and September 10, 2013, forty-seven patients were identified. Median age was 42.4 years. Thirty-one (66.0%) were women. A majority were Caucasian (68.1%). At diagnosis, 43 (91.5%) patients had ascites, 27 (57.4%) patients had a hematologic disorder associated with a hypercoagulable state and 26 (55.3%) had cirrhosis. Forty (85.1%) patients were on anticoagulation (AC), 30 (63.8%) of whom were maintained on warfarin. Two patients (4.3%) underwent thrombolytic therapy. A transjugular intrahepatic portosystemic shunt (TIPS) was placed in 21 (44.7%) patients, 19 (90.5%) of whom were also on AC. Twenty-one (44.7%) received AC alone. Over a median of 974 d, 8 (17.0%) patients received LT, and 10 (21.3%) died. The median time from listing to death was 26 mo [interquartile range (IQR) = 16, 65)]. TIPS with AC was utilized more frequently in younger patients (P = 0.02). Age, cirrhosis and chronic kidney disease (CKD) were significant predictors of LT or death.
CONCLUSION: AC alone was employed as frequently as TIPS with AC, though the latter was used more frequently in younger patients with polycythemia vera. There were no significant differences in treatment outcome regardless of the therapeutic intervention employed. Significant predictors of poor prognosis included age, cirrhosis and CKD.

Entities:  

Keywords:  Anticoagulation; Budd-Chiari syndrome; Hepatic vein thrombosis; Liver transplantation; Transjugular intrahepatic portosystemic shunt

Mesh:

Substances:

Year:  2014        PMID: 25473178      PMCID: PMC4239512          DOI: 10.3748/wjg.v20.i43.16236

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting.

Authors:  G Zeitoun; S Escolano; A Hadengue; N Azar; M El Younsi; A Mallet; M J Boudet; J M Hay; S Erlinger; J P Benhamou; J Belghiti; D Valla
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

Review 2.  Budd-Chiari syndrome: a review by an expert panel.

Authors:  Harry L A Janssen; Juan-Carlos Garcia-Pagan; Elwyn Elias; Gilles Mentha; Antoine Hadengue; Dominique-Charles Valla
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

Review 3.  The Budd-Chiari syndrome.

Authors:  K V Narayanan Menon; Vijay Shah; Patrick S Kamath
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

4.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  [Study on clinical features and etiology of primary Budd-Chiari Syndrome].

Authors:  De-lei Cheng; Hao Xu; Rong Hua; Xin-jian Xu; Hong-tao Du; Huan Qiu
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2013-11

Review 6.  The Budd-Chiari syndrome.

Authors:  Rania Hefaiedh; Mariem Cheikh; Lobna Marsaoui; Rym Ennaifer; Hayfa Romdhane; Houda Ben Nejma; Najet Bel Hadj; Nafaa Arfa; Mohamed Taher Khalfallah
Journal:  Tunis Med       Date:  2013-06

7.  Budd-Chiari syndrome: current management options.

Authors:  D P Slakey; A S Klein; A C Venbrux; J L Cameron
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

Review 8.  Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Authors:  Richard Parker
Journal:  Clin Liver Dis       Date:  2014-05       Impact factor: 6.126

9.  Portal hypertension.

Authors:  J K Banerjee
Journal:  Med J Armed Forces India       Date:  2012-07

10.  Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers.

Authors:  Dominique Cazals-Hatem; Valérie Vilgrain; Pascal Genin; Marie-Hélène Denninger; François Durand; Jacques Belghiti; Dominique Valla; Claude Degott
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

View more
  9 in total

1.  Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease.

Authors:  Takuya Wakamatsu; Suguru Yamamoto; Kenya Kamimura; Takeshi Nakatsue; Noriaki Iino; Seitaro Iguchi; Yoshikatsu Kaneko; Shin Goto; Junichiro James Kazama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2015-12-11

2.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

3.  Budd- Chiari Syndrome as an Initial Manifestation of Systemic Lupus Erythematosus.

Authors:  Jayabal Pandiaraja; Arumugam Sathyaseelan
Journal:  J Clin Diagn Res       Date:  2016-04-01

4.  A Nationwide Analysis of Budd-Chiari Syndrome in the United States.

Authors:  Joseph J Alukal; Talan Zhang; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2020-08-15

5.  Budd-Chiari Syndrome: an unnoticed diagnosis.

Authors:  Camila Kruschewsky Falcão; Gustavo C Freitas Fagundes; Gustavo Checolli Lamos; Aloisio Felipe-Silva; Silvana Maria Lovisolo; João Augusto Martines; Fernando Peixoto Ferraz de Campos
Journal:  Autops Case Rep       Date:  2015-06-30

6.  Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study.

Authors:  Mohammad Sakr; Sara M Abdelhakam; Soheir A Elsayed; Enas H Allam; Amir M Farid; Waleed Abdelmoaty; Azza M Hassan; Mohamed Shaker; Mohamed El-Gharib; Ahmed Eldorry
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

7.  Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model.

Authors:  De-Lei Cheng; Nan Zhu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Ya Liu; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

8.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

Review 9.  Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review.

Authors:  Riccardo Inchingolo; Alessandro Posa; Martin Mariappan; Tiago Kojun Tibana; Thiago Franchi Nunes; Stavros Spiliopoulos; Elias Brountzos
Journal:  World J Gastroenterol       Date:  2020-09-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.